Phase II trial of gimatecan in patients with recurrent epithelial ovarian, fallopian or peritoneal cancer in China

Trial Profile

Phase II trial of gimatecan in patients with recurrent epithelial ovarian, fallopian or peritoneal cancer in China

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Aug 2013

At a glance

  • Drugs Gimatecan (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Sponsors Lees Pharmaceutical Holdings
  • Most Recent Events

    • 07 Aug 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top